Latest filing published 24 Feb 2026 for TELA Bio, Inc..
Not enough buy signals with a settled T+90 horizon to measure a track record yet.
Megan Smeykal (senior executive) discloses dealings in TELA Bio, Inc. to SEC (Form 4). Between 23 February 2022 and 23 February 2026, the trades on record add up to 21 filings.
The filings describe grants, exercises and other transfers rather than trades on the open market. Grants and option exercises follow pay plans set in advance, so they reveal less about an insider's own view than a purchase made with personal money.
The latest filing, published on 24 February 2026, reports a share grant of €274 in TELA Bio, Inc. The median gap between a trade and its publication by SEC (Form 4) is 2 days. US insiders must file a Form 4 within two business days of a trade. Every figure here comes from the filings published by SEC (Form 4) and describes the past, not future prices; it is not investment advice.
Open company profiles for insider transactions, fundamentals and analyst consensus when available.
13 of 13 declarations